Real-World Analysis of Exacerbations and Exacerbation-Related Costs Among Patients with Asthma Receiving Tezepelumab (CROSSROADS-5) (20240066)First published 28/03/2025 Last updated 01/04/2025 EU PAS number: EUPAS1000000514StudyOngoing